PedAM
Pediatric Disease Annotations & Medicines
| Disease | breast cancer |
| Phenotype | C0007099|carcinoma in situ |
| Sentences | 13 |
| PubMedID- 20929881 | Background: we examined whether mammographic density predicts risk of second breast cancers among patients with ductal carcinoma in situ (dcis). |
| PubMedID- 20448386 | One female breast cancer was diagnosed with ductal carcinoma in situ (dcis) cancer. |
| PubMedID- 24147085 | Development and evaluation of a prediction model for underestimated invasive breast cancer in women with ductal carcinoma in situ at stereotactic large core needle biopsy. |
| PubMedID- 21358094 | Patterns of practices with respect to locoregional treatment of breast cancer in patients with ductal carcinoma in situ, early breast cancer (ebc), locally advanced and metastatic breast cancer (mbc) were studied. |
| PubMedID- 20124477 | Quantitative immunohistochemistry revealed elevated bcl6 in high-grade and metastatic breast cancer compared with ductal carcinoma in situ and nonmalignant breast, and cellular bcl6 protein levels correlated negatively with nuclear stat5a (r = -0.52; p < 0.001) but not with stat5b. |
| PubMedID- 22458606 | These markers were previously shown to indicate compromised rb signaling and predict subsequent tumor events in breast cancer patients diagnosed with ductal carcinoma in situ [33]. |
| PubMedID- 24064317 | Risk of local failure in breast cancer patients with lobular carcinoma in situ at the final surgical margins: is re-excision necessary. |
| PubMedID- 24159387 | We show that, when compared to biennial and nonregular screeners, regular screeners were more likely to present with early breast cancer, including carcinoma in situ (27%) and stage i (53%) invasive breast cancer. |
| PubMedID- 24615647 | Is carcinoma in situ a precursor lesion of invasive breast cancer. |
| PubMedID- 26265211 | Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer. |
| PubMedID- 21894562 | The aim of this study was to investigate the prevalence of slit2 promoter hypermethylation in both the tumor and serum samples of breast cancer patients with ductal carcinoma in situ (dcis) or invasive breast carcinoma (ibc). |
| PubMedID- 22417857 | However, although the exclusion is declared in the absence of her-2/neu gene amplification (ratio her-2/neu/cep-17 <1.8) according to the american society of clinical oncology/college of american pathologists recommendations, there are borderline cases (1.8 |
| PubMedID- 26259752 | Additionally, the use of cpm has more than doubled in the last decade, and this increase is noted among all stages of breast cancer, even in patients with ductal carcinoma in situ (stage 0). |
Page: 1